ERBB2 and breast carcinoma: Our results demonstrate the efficacy of the combination AUT for ERα + /HER2-/PI3Kα-mutant breast cancer cells (Fig. 4A, B, and Fig. S9A), and the benefit of adding talazoparib to AUT, the combination AUTTala, in long-term treatments (Fig. 6F, G).